Immune profiling of antigen—specific B cell
CB
Published · 36 slides · 0 views
1 / 1
Description
Immune profiling of antigenspecific B cell responses to HIV vaccine immunogens in HVTN clinical trials Pre-conference: Advancing HIV prevention science and access K. Rachael Parks, Fred Hutch, Seattle WA lineage based, germline targeting,
Related Topics
Share
Embed code
Download this presentation From Below
"Immune profiling of antigen—specific B cell" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Presentation Transcript
01
Immune profiling of antigen—specific B cell responses to HIV vaccine immunogens in HVTN clinical trials Pre-conference: Advancing HIV prevention science and access K. Rachael Parks, Fred Hutch, Seattle WA<br>
02
lineage based, germline targeting, trimer-based immunogen design strategies Phase I HVTN clinical trials evaluate HIV Env based immunogens aiming to induce broadly neutralizing antibodies<br>
03
lineage based, germline targeting, trimer-based immunogen design strategies
BnAbs have conserved genetic features which serve as a “biomarker” for clinical trial endpoints Antigen binding region Phase I HVTN clinical trials evaluate HIV Env based immunogens aiming to induce broadly neutralizing antibodies<br>
BnAbs have conserved genetic features which serve as a “biomarker” for clinical trial endpoints Antigen binding region Phase I HVTN clinical trials evaluate HIV Env based immunogens aiming to induce broadly neutralizing antibodies<br>
04
lineage based, germline targeting, trimer-based immunogen design strategies
BnAbs have conserved genetic features which serve as a “biomarker” for clinical trial endpoints
To determine the induction of bnAb lineages by vaccination, we interrogate the vaccine-elicited B cell repertoire Antigen binding region Phase I HVTN clinical trials evaluate HIV Env based immunogens aiming to induce broadly neutralizing antibodies<br>
BnAbs have conserved genetic features which serve as a “biomarker” for clinical trial endpoints
To determine the induction of bnAb lineages by vaccination, we interrogate the vaccine-elicited B cell repertoire Antigen binding region Phase I HVTN clinical trials evaluate HIV Env based immunogens aiming to induce broadly neutralizing antibodies<br>
05
Methods to identify vaccine-specific B cell frequencies and determine their genetic features<br>
06
Methods to identify vaccine-specific B cell frequencies and determine their genetic features<br>
07
Methods to identify vaccine-specific B cell frequencies and determine their genetic features 7 Flow Antibodies<br>
08
Methods to identify vaccine-specific B cell frequencies and determine their genetic features Flow Antibodies Use flow cytometry: to determine vaccine-specific and epitope-specific B cell frequencies<br>
09
N332-GT5++ N332-GT5 KO++ (V3 glycan KO) Methods to identify vaccine-specific B cell frequencies and determine their genetic features 9 Flow Antibodies Use flow cytometry: to determine vaccine-specific and epitope-specific B cell frequencies HVTN 144<br>
10
N332-GT5++ N332-GT5 KO++ (V3 glycan KO) Methods to identify vaccine-specific B cell frequencies and determine their genetic features 10 Flow Antibodies Use flow cytometry: to determine vaccine-specific and epitope-specific B cell frequencies Epitope-specific Non-epitope specific HVTN 144<br>
11
Methods to identify vaccine-specific B cell frequencies and determine their genetic features Flow Antibodies Using cell sorting: isolate vaccine-specific memory B cells<br>
12
Methods to identify vaccine-specific B cell frequencies and determine their genetic features 12 Flow Antibodies Using cell sorting: isolate vaccine-specific memory B cells Sequence B cell receptor using 10x genomics pipeline<br>
13
Library preparation and sequencing using 10x genomics Droplet generation and RT Investigate BCR sequences for bnAb signatures Chromium Next GEM Single Cell 5' Reagent Kits v2 (Dual Index) NovaSeq X+ Target Reads:
BCR: 10k<br>
BCR: 10k<br>
14
Library preparation and sequencing using 10x genomics 14 Droplet generation and RT Investigate BCR sequences for bnAb signatures Chromium Next GEM Single Cell 5' Reagent Kits v2 (Dual Index) NovaSeq X+ Target Reads:
BCR: 10k For example, VRC01: VH1-2*02 or *04 HC, 5 AA CDRL3<br>
BCR: 10k For example, VRC01: VH1-2*02 or *04 HC, 5 AA CDRL3<br>
15
Identify bnAb precursors against multiple HIV Env epitopes HIV-1 Env trimer Study: HVTN 144
Immunogen/Adjuvant: N332-GT5 gp140/SMNP
Epitope: N332-glycan
bnAb precursor: BG18-class<br>
Immunogen/Adjuvant: N332-GT5 gp140/SMNP
Epitope: N332-glycan
bnAb precursor: BG18-class<br>
16
Identify bnAb precursors against multiple HIV Env epitopes HIV-1 Env trimer Study: HVTN 144
Immunogen/Adjuvant: N332-GT5 gp140/SMNP
Epitope: N332-glycan
bnAb precursor: BG18-class Type I BG18 precursors: 100%
Type II BG18 precursors: 94-100% Results are based on the bioinformatic definition for the bnAb class<br>
Immunogen/Adjuvant: N332-GT5 gp140/SMNP
Epitope: N332-glycan
bnAb precursor: BG18-class Type I BG18 precursors: 100%
Type II BG18 precursors: 94-100% Results are based on the bioinformatic definition for the bnAb class<br>
17
Identify bnAb precursors against multiple HIV Env epitopes HIV-1 Env trimer Study: HVTN 305
Immunogen: eOD-GT8 DNA plasmid
Epitope: CD4-binding site
bnAb precursor: VRC01-class Results are based on the bioinformatic definition for the bnAb class<br>
Immunogen: eOD-GT8 DNA plasmid
Epitope: CD4-binding site
bnAb precursor: VRC01-class Results are based on the bioinformatic definition for the bnAb class<br>
18
Identify bnAb precursors against multiple HIV Env epitopes HIV-1 Env trimer Study: HVTN 301
Immunogen: 426c.Mod.Core-C4b
Epitope: CD4-binding site
bnAb precursor: VRC01-class<br>
Immunogen: 426c.Mod.Core-C4b
Epitope: CD4-binding site
bnAb precursor: VRC01-class<br>
19
Identify bnAb precursors against multiple HIV Env epitopes HIV-1 Env trimer Study: HVTN 301
Immunogen: 426c.Mod.Core-C4b
Epitope: CD4-binding site
bnAb precursor: VRC01-class 18-40% VRC01-class response rate Results are based on the bioinformatic definition for the bnAb class<br>
Immunogen: 426c.Mod.Core-C4b
Epitope: CD4-binding site
bnAb precursor: VRC01-class 18-40% VRC01-class response rate Results are based on the bioinformatic definition for the bnAb class<br>
20
In People Living with and without HIV Immunogen: 426c.Mod.Core-C4b
Epitope: CD4-binding site
bnAb precursor: VRC01-class HVTN 301:
People living without HIV HVTN 807:
People living with HIV HIV-1 Env trimer<br>
Epitope: CD4-binding site
bnAb precursor: VRC01-class HVTN 301:
People living without HIV HVTN 807:
People living with HIV HIV-1 Env trimer<br>
21
bnAb precursors elicited in People Living with and without HIV Immunogen: 426c.Mod.Core-C4b
Epitope: CD4-binding site
bnAb precursor: VRC01-class HVTN 301:
People living without HIV HVTN 807:
People living with HIV HIV-1 Env trimer Results are based on the bioinformatic definition for the bnAb class<br>
Epitope: CD4-binding site
bnAb precursor: VRC01-class HVTN 301:
People living without HIV HVTN 807:
People living with HIV HIV-1 Env trimer Results are based on the bioinformatic definition for the bnAb class<br>
22
In Summary Developed methodological pipeline to detect bnAb precursors and neutralizing antibody lineages following vaccination with Env immunogens<br>
23
In Summary Developed methodological pipeline to detect bnAb precursors and neutralizing antibody lineages following vaccination with Env immunogens
bnAb precursors against multiple HIV Env epitopes: CD4-BS and V3-glycan
Boosting studies are ongoing to determine if we can increase the neutralizing activity of the bnAb precursor lineages (HVTN 301 boost, collaborations with DHVI)<br>
bnAb precursors against multiple HIV Env epitopes: CD4-BS and V3-glycan
Boosting studies are ongoing to determine if we can increase the neutralizing activity of the bnAb precursor lineages (HVTN 301 boost, collaborations with DHVI)<br>
24
In Summary Developed methodological pipeline to detect bnAb precursors and neutralizing antibody lineages following vaccination with Env immunogens
bnAb precursors against multiple HIV Env epitopes: CD4-BS and V3-glycan
Boosting studies are ongoing to determine if we can increase the neutralizing activity of the bnAb precursor lineages (HVTN 301 boost, collaborations with DHVI)
bnAb precursors elicited in diverse populations: people living with HIV and people living without HIV<br>
bnAb precursors against multiple HIV Env epitopes: CD4-BS and V3-glycan
Boosting studies are ongoing to determine if we can increase the neutralizing activity of the bnAb precursor lineages (HVTN 301 boost, collaborations with DHVI)
bnAb precursors elicited in diverse populations: people living with HIV and people living without HIV<br>
25
In Summary Developed methodological pipeline to detect bnAb precursors and neutralizing antibody lineages following vaccination with Env immunogens
bnAb precursors against multiple HIV Env epitopes: CD4-BS and V3-glycan
Boosting studies are ongoing to determine if we can increase the neutralizing activity of the bnAb precursor lineages (HVTN 301 boost, collaborations with DHVI)
bnAb precursors elicited in diverse populations: people living with HIV and people living without HIV
Tier 2, autologous neutralizing antibodies elicited by vaccination: protein (Hahn and Parks et al., 2024) and mRNA platforms (Parks et al., 2025)
One mAb with Tier 2, heterologous neutralization<br>
bnAb precursors against multiple HIV Env epitopes: CD4-BS and V3-glycan
Boosting studies are ongoing to determine if we can increase the neutralizing activity of the bnAb precursor lineages (HVTN 301 boost, collaborations with DHVI)
bnAb precursors elicited in diverse populations: people living with HIV and people living without HIV
Tier 2, autologous neutralizing antibodies elicited by vaccination: protein (Hahn and Parks et al., 2024) and mRNA platforms (Parks et al., 2025)
One mAb with Tier 2, heterologous neutralization<br>
26
In Summary Developed methodological pipeline to detect bnAb precursors and neutralizing antibody lineages following vaccination with Env immunogens
bnAb precursors against multiple HIV Env epitopes: CD4-BS and V3-glycan
Boosting studies are ongoing to determine if we can increase the neutralizing activity of the bnAb precursor lineages (HVTN 301 boost, collaborations with DHVI)
bnAb precursors elicited in diverse populations: people living with HIV and people living without HIV
Tier 2, autologous neutralizing antibodies elicited by vaccination: protein (Hahn and Parks et al., 2024) and mRNA platforms (Parks et al., 2025)
One mAb with Tier 2, heterologous neutralization
Pipeline assessed distinct tissue types: blood, lymph node, bone marrow (data not shown)<br>
bnAb precursors against multiple HIV Env epitopes: CD4-BS and V3-glycan
Boosting studies are ongoing to determine if we can increase the neutralizing activity of the bnAb precursor lineages (HVTN 301 boost, collaborations with DHVI)
bnAb precursors elicited in diverse populations: people living with HIV and people living without HIV
Tier 2, autologous neutralizing antibodies elicited by vaccination: protein (Hahn and Parks et al., 2024) and mRNA platforms (Parks et al., 2025)
One mAb with Tier 2, heterologous neutralization
Pipeline assessed distinct tissue types: blood, lymph node, bone marrow (data not shown)<br>
27
426c.Mod.Core-C4b design and preclinical testing Adriana Lippy
Andrew McGuire
Andrew Riker
Andy Stuart
Anita Dryer
Anna MacCamy
Arineh Khechaduri
Brittany Takushi
Colin Correnti
Connor Weidle
Gargi Kher
George Sellhorn
Jolene Glen
Josephine Trichka
Kelsey Salladay
Parul Agrawal
Jerome Edwards
Karli Hinton
Derin Hara Alexander Gitlin
Hugo Mouquet
Johannes Scheid
Michel Nussenzweig
Natalia Freund
Pia Dosenovic Antony West
Courtney Chen
Han Gao
Louise Scharf
Pamela Bjorkman
Siduo Jiang
Stuart Sieves Andrew Ward
Gabe Ozorowski
Joseph Jardine
Sergey Menis
William Schief David Montefiori
Shaunna Shen Anika Naidu
Po-Ssu Huang Katherine Ellingson
Kristi Giger
Kristen Cohen
Matt Gray
Marie Pancera
Noah Sather
Parul Agrawal
Roland Strong
Sam Hoot
Sara Carbonetti
Yu-Ru Lin
Zane Kraft The Rockefeller University Stanford University CalTech TSRI Duke University SBRI / Fred Hutch<br>
Andrew McGuire
Andrew Riker
Andy Stuart
Anita Dryer
Anna MacCamy
Arineh Khechaduri
Brittany Takushi
Colin Correnti
Connor Weidle
Gargi Kher
George Sellhorn
Jolene Glen
Josephine Trichka
Kelsey Salladay
Parul Agrawal
Jerome Edwards
Karli Hinton
Derin Hara Alexander Gitlin
Hugo Mouquet
Johannes Scheid
Michel Nussenzweig
Natalia Freund
Pia Dosenovic Antony West
Courtney Chen
Han Gao
Louise Scharf
Pamela Bjorkman
Siduo Jiang
Stuart Sieves Andrew Ward
Gabe Ozorowski
Joseph Jardine
Sergey Menis
William Schief David Montefiori
Shaunna Shen Anika Naidu
Po-Ssu Huang Katherine Ellingson
Kristi Giger
Kristen Cohen
Matt Gray
Marie Pancera
Noah Sather
Parul Agrawal
Roland Strong
Sam Hoot
Sara Carbonetti
Yu-Ru Lin
Zane Kraft The Rockefeller University Stanford University CalTech TSRI Duke University SBRI / Fred Hutch<br>
28
HVTN 301 Protocol Team Acknowledgements Chair
Hyman Scott
Co-chair
Kristen Cohen
Nathifa Moyo
Protocol Team Leader
Will Hahn
Statistician
Ollivier Hyrien
Medical Officers
Peggy Yacovone
Lab Leads
John Hural CAB Members
Paul Marcelin
Hakeem White
CER
Rafael Gonzalez
CEU Representative
Gail Broder
Clinic Coordinators
Theresa Wagner
Clinical Safety Specialist
Megan Jones
Clinical Trials Manager
India Tindale
Data Management
Brian Ingersoll
April Randhawa
Developer Representatives
Leo Stamatatos, FH
Mingchao Shen, FH
Zachary Sagawa, AAHI
Tom Hassell, IAVI
DAIDS Lab Lead
Milton Maciel
DAIDS Product Lead
Sujata Vijh
Lab Representative
Jen Hanke
Project Coordinator
Anders McConachie
Genneva MachMiller
Protocol Development Manager
Meg Trahey
Protocol Pharmacist
Oladapo Alli
Regulatory Affairs
Laurie Rinn
Statistics
Randy Burnham<br>
Hyman Scott
Co-chair
Kristen Cohen
Nathifa Moyo
Protocol Team Leader
Will Hahn
Statistician
Ollivier Hyrien
Medical Officers
Peggy Yacovone
Lab Leads
John Hural CAB Members
Paul Marcelin
Hakeem White
CER
Rafael Gonzalez
CEU Representative
Gail Broder
Clinic Coordinators
Theresa Wagner
Clinical Safety Specialist
Megan Jones
Clinical Trials Manager
India Tindale
Data Management
Brian Ingersoll
April Randhawa
Developer Representatives
Leo Stamatatos, FH
Mingchao Shen, FH
Zachary Sagawa, AAHI
Tom Hassell, IAVI
DAIDS Lab Lead
Milton Maciel
DAIDS Product Lead
Sujata Vijh
Lab Representative
Jen Hanke
Project Coordinator
Anders McConachie
Genneva MachMiller
Protocol Development Manager
Meg Trahey
Protocol Pharmacist
Oladapo Alli
Regulatory Affairs
Laurie Rinn
Statistics
Randy Burnham<br>
29
HVTN 301 Acknowledgements Thank you to the Statistical and Data Management Center.
Funders & Other Collaborators
NIAID/DAIDS
Access to Advanced Health Institute (AAHI)
International AIDS Vaccine Initiative (IAVI)<br>
Funders & Other Collaborators
NIAID/DAIDS
Access to Advanced Health Institute (AAHI)
International AIDS Vaccine Initiative (IAVI)<br>
30
Thank you to all the site investigators, clinic coordinators, CER teams, and pharmacists.HVTN 301 sites: Atlanta – Ponce de Leon
Birmingham
Boston – Brigham
New York – Columbia Physicians & Surgeons
Seattle
San Francisco<br>
Birmingham
Boston – Brigham
New York – Columbia Physicians & Surgeons
Seattle
San Francisco<br>
31
7/17/26 31 HVTN 144 Protocol Team and funding Chair
Lindsey Baden
Co-chair
Deborah Theodore
Protocol Team Leader
Will Hahn
Statistician
Bo Zhang
Medical Officers
Edith Swann
Lab Leads
Georgia Tomaras CAB Members
Gary Daffin
John Sefakis
CER
Emily Koleske
CEU Representative
Luciana Kamel
Gail Broder
Daniel Driffin
Louis Shackelford
Clinic Coordinators
August Heithoff
Clinical Safety Specialist
Nadia McCloskey
Clinical Trials Manager
Julie Hunt
Data Management
Anna Leonen
Jessica Andriesen
April Randhawa
Developer Representatives
William Schief
Darrell Irvine
DAIDS Product Lead
Angela Malaspina
Lab Representative
Pam Witte
Jen Hanke
Protocol Development Manager
Diana Koch
Meg Trahey
Protocol Pharmacist
Shawn Chiambah
Regulatory Affairs
Meg Brandon
Statistics
Shiyu Chen, Zihan Zheng
Technical Editor
Soni Hingorani-Giles<br>
Lindsey Baden
Co-chair
Deborah Theodore
Protocol Team Leader
Will Hahn
Statistician
Bo Zhang
Medical Officers
Edith Swann
Lab Leads
Georgia Tomaras CAB Members
Gary Daffin
John Sefakis
CER
Emily Koleske
CEU Representative
Luciana Kamel
Gail Broder
Daniel Driffin
Louis Shackelford
Clinic Coordinators
August Heithoff
Clinical Safety Specialist
Nadia McCloskey
Clinical Trials Manager
Julie Hunt
Data Management
Anna Leonen
Jessica Andriesen
April Randhawa
Developer Representatives
William Schief
Darrell Irvine
DAIDS Product Lead
Angela Malaspina
Lab Representative
Pam Witte
Jen Hanke
Protocol Development Manager
Diana Koch
Meg Trahey
Protocol Pharmacist
Shawn Chiambah
Regulatory Affairs
Meg Brandon
Statistics
Shiyu Chen, Zihan Zheng
Technical Editor
Soni Hingorani-Giles<br>
32
IAVI
Sam Pallerla
Al Price
Angela Lombardo
Sreenivas Avula
Thomas Hassell
Vaneet Sharma
Jim Ackland
Antu Dey
Melissa Schroeter
Ryan Swoyer
Sandip Patel
Eddy Sayeed Scripps/CHAVD
Sal Butera
John Rizzo
Bill Schief
Jon Steichen
Sergey Menis
Bettina Groschel
Alesslia Liguori
Oleks Kalyuzhniy
Chris Cottrell
Darrell Irvine
Ivan Pires
Mariane Melo
Murillo Silva
Jim Paulson
John Yates
Sabyasachi Baboo
Andrew Ward
Gabe Ozorowski
Max Crispin
Joel Allen N332-GT5/SMNP manufacturing NIH
Michael Pensiero
Angela Malaspina
Michael Eller
Cesar Boggiano<br>
Sam Pallerla
Al Price
Angela Lombardo
Sreenivas Avula
Thomas Hassell
Vaneet Sharma
Jim Ackland
Antu Dey
Melissa Schroeter
Ryan Swoyer
Sandip Patel
Eddy Sayeed Scripps/CHAVD
Sal Butera
John Rizzo
Bill Schief
Jon Steichen
Sergey Menis
Bettina Groschel
Alesslia Liguori
Oleks Kalyuzhniy
Chris Cottrell
Darrell Irvine
Ivan Pires
Mariane Melo
Murillo Silva
Jim Paulson
John Yates
Sabyasachi Baboo
Andrew Ward
Gabe Ozorowski
Max Crispin
Joel Allen N332-GT5/SMNP manufacturing NIH
Michael Pensiero
Angela Malaspina
Michael Eller
Cesar Boggiano<br>
33
7/17/26 33 HVTN 305 Protocol Team Acknowledgements Chair
Sonya Heath
Co-chairs
Amy Sherman
Nivashnee Naicker
Protocol Team Leaders
Will Hahn
Briana Furch
Statistician
Ollivier Hyrien
Medical Officers
Chris Duplessis
Lab Leads
Guido Ferrari CAB Members
Sibusiso Mngadi
Rick Church
CER
Andres Avila Paz
CEU Representative
Gail Broder
Kagisho Baepanye
Matshidiso Malefo
Clinic Coordinators
Bongi Zuma
Clinical Safety Specialist
Nadia McCloskey
Clinical Trials Manager
Lori Proulx-Burns
DAIDS Product Lead
Sujata Vijh
Data Management
Jennifer Schille
Andrea Repetto
April Randhawa
Developer Representatives
David Weiner, Wistar
Dan Kulp, Wistar
Laurent Humeau, INOVIO
Linda Dickinson, INOVIO
Lucio Gama, VRC
Lab Representative
Jessica Brown
Protocol Development Manager
Smitha Sripathy
Meg Trahey
Protocol Pharmacist
Justine Beck
Rochelle Rogers
Regional Medical Liaison
Simone Hendricks
Azwi Takalani
Regulatory Affairs
Meg Brandon
Statistics
Randy Burnham<br>
Sonya Heath
Co-chairs
Amy Sherman
Nivashnee Naicker
Protocol Team Leaders
Will Hahn
Briana Furch
Statistician
Ollivier Hyrien
Medical Officers
Chris Duplessis
Lab Leads
Guido Ferrari CAB Members
Sibusiso Mngadi
Rick Church
CER
Andres Avila Paz
CEU Representative
Gail Broder
Kagisho Baepanye
Matshidiso Malefo
Clinic Coordinators
Bongi Zuma
Clinical Safety Specialist
Nadia McCloskey
Clinical Trials Manager
Lori Proulx-Burns
DAIDS Product Lead
Sujata Vijh
Data Management
Jennifer Schille
Andrea Repetto
April Randhawa
Developer Representatives
David Weiner, Wistar
Dan Kulp, Wistar
Laurent Humeau, INOVIO
Linda Dickinson, INOVIO
Lucio Gama, VRC
Lab Representative
Jessica Brown
Protocol Development Manager
Smitha Sripathy
Meg Trahey
Protocol Pharmacist
Justine Beck
Rochelle Rogers
Regional Medical Liaison
Simone Hendricks
Azwi Takalani
Regulatory Affairs
Meg Brandon
Statistics
Randy Burnham<br>
34
7/17/26 34 HVTN 305 Acknowledgements Thank you to the Statistical and Data Management Center.
Funders & Other Collaborators
NIAID/DAIDS
The Wistar Institute
The Betty and Dale Bumpers Vaccine Research Center (VRC)
Inovio Pharmaceutical
Access to Advanced Health Institute (AAHI)<br>
Funders & Other Collaborators
NIAID/DAIDS
The Wistar Institute
The Betty and Dale Bumpers Vaccine Research Center (VRC)
Inovio Pharmaceutical
Access to Advanced Health Institute (AAHI)<br>
35
7/17/26 35 Thank you to all the site investigators, clinic coordinators, CER teams, and pharmacists.HVTN 305 sites: Birmingham
Boston – Brigham
San Francisco
Durban – eThekwini
Soweto – Bara
Cape Town – Groote Schuur<br>
Boston – Brigham
San Francisco
Durban – eThekwini
Soweto – Bara
Cape Town – Groote Schuur<br>
36
Laboratory and Analysis Team FHCC
Julie McElrath
Stephen DeRosa
Nathifa Moyo
Mingchao Shen
Lamar Fleming
Aaron Seese
Katharine Schwedhelm
Todd Haight
Carol Marty
Jacob Jordan
Constanza Marini-Macouzet
Suraj Prabhu
Liam Cheves
Maleia McBride
Andrew Markham
Avery Schmidt
Erica Phelps
Janice Fajardo
All Endpoints Technicians Duke
Georgia Tomaras
Yong Lin
Lu Zhang
Jack Heptinstall
Kelly Seaton
David Montefiori
Elize Domin
Haili Tang
Wenhong Feng
Arianna Mathewson Operations (FHCC)
John Hural
Jen Hanke
Ryan Jensen
Pam Witte
Rachel Lederer SDMC
Bo Zhang
April Randhawa
Zihan Zheng
Shannon Grant
Jia Jin Kee SCHARP
Erik Goosmann
Radhika Etikala Scripps
Bill Schief
Jon Steichen
Oleksandr Kalyuzhniy
Chris Cottrell
Yumiko Adachi
Danny Lu
Diana Goodwin
Ryan Tingle
Andrew Ward
Gabe Ozorowski
Wilma Lee
Swastik Phulera
Andy Tran FHCC
Ollivier Hyrien
Kellie MacPhee
Mike Duff
Ju Yeong Kim<br>
Julie McElrath
Stephen DeRosa
Nathifa Moyo
Mingchao Shen
Lamar Fleming
Aaron Seese
Katharine Schwedhelm
Todd Haight
Carol Marty
Jacob Jordan
Constanza Marini-Macouzet
Suraj Prabhu
Liam Cheves
Maleia McBride
Andrew Markham
Avery Schmidt
Erica Phelps
Janice Fajardo
All Endpoints Technicians Duke
Georgia Tomaras
Yong Lin
Lu Zhang
Jack Heptinstall
Kelly Seaton
David Montefiori
Elize Domin
Haili Tang
Wenhong Feng
Arianna Mathewson Operations (FHCC)
John Hural
Jen Hanke
Ryan Jensen
Pam Witte
Rachel Lederer SDMC
Bo Zhang
April Randhawa
Zihan Zheng
Shannon Grant
Jia Jin Kee SCHARP
Erik Goosmann
Radhika Etikala Scripps
Bill Schief
Jon Steichen
Oleksandr Kalyuzhniy
Chris Cottrell
Yumiko Adachi
Danny Lu
Diana Goodwin
Ryan Tingle
Andrew Ward
Gabe Ozorowski
Wilma Lee
Swastik Phulera
Andy Tran FHCC
Ollivier Hyrien
Kellie MacPhee
Mike Duff
Ju Yeong Kim<br>